Literature DB >> 8223760

Late potentials in arrhythmogenic right ventricular dysplasia. Prevalence, diagnostic and prognostic values.

J F Leclercq1, P Coumel.   

Abstract

A time-domain signal-averaged ECG was performed in 52 patients with arrhythmogenic right ventricular dysplasia (ARVD) proven by angiography, in 45 control subjects with normal hearts, and in 132 patients with various types of ventricular arrhythmias and no evidence of cardiac disease during routine cardiac examination. Based on the results of control subjects, patients with at least 2/3 abnormal parameters (QRS > or = 113 ms, LAS > or = 38 ms, RMS 40 < or = 16 microV) were considered as having late potentials (LP). Prevalence of LP was 75% (39/52) in patients with ARVD, 19% (25/132) in patients with apparently idiopathic ventricular arrhythmias, and 4% (4/45) in controls (P < 0.01). In ARVD, no relationship was found between LP and age, type of ventricular arrhythmia (sustained or not), or extent of the disease on angiography. A significant correlation was found between the values of two parameters (QRS and LAS length) and the delay between the first ventricular arrhythmia and the examination (r = 0.39 and 0.42 respectively, P < 0.01). Further examinations (echo and/or angiography) revealed underlying heart disease in 26/132 patients with apparently normal hearts, including 13 with ARVD. LP were present in 21/26 patients (81%) with diseased heart vs 4/106 (4%) in those with normal hearts after complete examination, giving a sensitivity of 86%, and a specificity of 96% for detecting underlying heart disease. During a follow-up of 3.1 +/- 1.2 years after signal-averaged ECG, only one patient died from heart failure.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8223760     DOI: 10.1093/eurheartj/14.suppl_e.80

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  7 in total

Review 1.  [Arrhythmogenic right ventricular cardiomyopathy. Etiology, diagnosis and therapy].

Authors:  T Wichter; M Borggrefe; G Breithardt
Journal:  Med Klin (Munich)       Date:  1998-04-15

2.  Risk stratification in arrhythmogenic right ventricular cardiomyopathy.

Authors:  M Silvano; D Corrado; J Köbe; G Mönnig; C Basso; G Thiene; L Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-10-11

Review 3.  Arrhythmogenic right ventricular cardiomyopathy: an update on pathophysiology, genetics, diagnosis, and risk stratification.

Authors:  M Paul; T Wichter; L Fabritz; J Waltenberger; E Schulze-Bahr; P Kirchhof
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2012-09-26

Review 4.  Noninvasive risk stratification in arrhythmogenic right ventricular cardiomyopathy.

Authors:  Pietro Turrini; Domenico Corrado; Cristina Basso; Andrea Nava; Gaetano Thiene
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-04       Impact factor: 1.468

Review 5.  Utility of SAECG in arrhythmogenic right ventricle dysplasia.

Authors:  Khurram Nasir; Julie Rutberg; Harikrishna Tandri; Ronald Berger; Gordon Tomaselli; Hugh Calkins
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-04       Impact factor: 1.468

Review 6.  The electrocardiogram in right ventricular cardiomyopathy/dysplasia. How can the electrocardiogram assist in understanding the pathologic and functional changes of the heart in this disease?

Authors:  Frank I Marcus; Wojciech Zareba
Journal:  J Electrocardiol       Date:  2009-02-04       Impact factor: 1.438

7.  Characteristics and clinical assessment of unexplained sudden cardiac arrest in the real-world setting: focus on idiopathic ventricular fibrillation.

Authors:  Victor Waldmann; Wulfran Bougouin; Nicole Karam; Florence Dumas; Ardalan Sharifzadehgan; Estelle Gandjbakhch; Vincent Algalarrondo; Kumar Narayanan; Alexandre Zhao; Denis Amet; Daniel Jost; Guillaume Geri; Lionel Lamhaut; Frankie Beganton; Bertrand Ludes; Patrick Bruneval; Isabelle Plu; Françoise Hidden-Lucet; Juliette Albuisson; Thomas Lavergne; Olivier Piot; Christine Alonso; Antoine Leenhardt; Nicolas Lellouche; Fabrice Extramiana; Alain Cariou; Xavier Jouven; Eloi Marijon
Journal:  Eur Heart J       Date:  2018-06-01       Impact factor: 29.983

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.